Pls like n comment ?-To The Moon - Tiger Brokers Online Investing Community - To The Moon

1
3
Favorite

KuehBulu
2021-05-25

Pls like n comment ?

NGM Stock Tumbles After Aldafermin Flunks In Mid-Stage NASH Study

NGM Biopharmaceuticals Inc (NASDAQ: NGM) has reported results from the 24-week Phase 2b ALPINE 2/3 s

NGM Stock Tumbles After Aldafermin Flunks In Mid-Stage NASH Study

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

1

Report

Comment（3）

Top
Latest

KinKin
·2021-05-25
Pls reply
Reply
Like
Report
Fold Replies
- KinKin:
  Sure
  2021-05-26
  Reply
  Report
- AndreR93:
  Reply pls
  2021-05-25
  Reply
  Report

Most Discussed

Terms and Conditions·Privacy Policy

Company: TTMF Limited. Tech supported by Xiangshang Yixin.

Email：uservice@ttm.financial

{"i18n":{"language":"en_US"},"data":{"magic":2,"id":131428145,"tweetId":"131428145","gmtCreate":1621877755287,"gmtModify":1704363759674,"author":{"id":3575830079167965,"idStr":"3575830079167965","authorId":3575830079167965,"authorIdStr":"3575830079167965","name":"KuehBulu","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":9,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":2,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p>Pls like n comment ?</p></body></html>","htmlText":"<html><head></head><body><p>Pls like n comment ?</p></body></html>","text":"Pls like n comment ?","highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":3,"repostSize":0,"favoriteSize":0,"link":"https://ttm.financial/post/131428145","repostId":2137155575,"repostType":4,"repost":{"id":"2137155575","kind":"news","pubTimestamp":1621868714,"share":"https://www.laohu8.com/m/news/2137155575?lang=&edition=full","pubTime":"2021-05-24 23:05","market":"us","language":"en","title":"NGM Stock Tumbles After Aldafermin Flunks In Mid-Stage NASH Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2137155575","media":"Benzinga","summary":"NGM Biopharmaceuticals Inc (NASDAQ: NGM) has reported results from the 24-week Phase 2b ALPINE 2/3 s","content":"<ul><li><b><a href=\"https://laohu8.com/S/NGM\">NGM Biopharmaceuticals Inc</a></b>&nbsp;(NASDAQ: NGM)&nbsp;has reported results&nbsp;from the 24-week Phase 2b ALPINE 2/3 study evaluating aldafermin in non-alcoholic steatohepatitis (NASH) patients with stage 2 or 3 liver fibrosis (F2/F3).</li><li>The study did not meet its primary endpoint evaluating a dose-response improvement in liver fibrosis by more than 1 stage with no worsening of NASH at week 24 (p=0.55).</li><li>The study did achieve statistical significance versus placebo on specific secondary endpoints, including NASH resolution (at the 3 mg dose) and multiple non-invasive measures of NASH, including liver fat content (at the 1 mg and 3 mg doses).</li><li>Given the failure to meet the primary endpoint, the company has decided not to pursue Phase 3 development of aldafermin in F2/F3 NASH; instead will focus on its ophthalmology and oncology portfolio.</li><li>The overall safety profile of aldafermin was consistent with prior studies and similar to that of placebo.</li><li>Patients treated with aldafermin at all three doses studied in the trial demonstrated a comparable frequency of adverse events versus placebo.</li><li>Additionally,&nbsp;<b>Merck &amp; Co Inc</b>&nbsp;(NYSE:&nbsp;MRK) continues the global Phase 2b development of MK-3655, an FGFR1c/KLB agonistic antibody for NASH treatment, which NGM discovered under its collaboration with Merck.</li><li>NGM will host a conference call and webcast with a slide presentation at 8:30 a.m. ET today.</li><li><b>Price Action:</b>&nbsp;NGM shares are trading 45.4% lower $15.5 in the premarket session on the last check Monday.</li></ul>","source":"yahoofinance","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>NGM Stock Tumbles After Aldafermin Flunks In Mid-Stage NASH Study</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNGM Stock Tumbles After Aldafermin Flunks In Mid-Stage NASH Study\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-05-24 23:05 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/ngm-stock-tumbles-aldafermin-flunks-115014442.html><strong>Benzinga</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>NGM Biopharmaceuticals Inc (NASDAQ: NGM) has reported results from the 24-week Phase 2b ALPINE 2/3 study evaluating aldafermin in non-alcoholic steatohepatitis (NASH) patients with stage 2 or 3 liver ...</p>\n\n<a href=\"https://finance.yahoo.com/news/ngm-stock-tumbles-aldafermin-flunks-115014442.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NGM":"NGM Biopharmaceuticals Inc","MRK":"默沙东"},"source_url":"https://finance.yahoo.com/news/ngm-stock-tumbles-aldafermin-flunks-115014442.html","is_english":true,"share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","article_id":"2137155575","content_text":"NGM Biopharmaceuticals Inc (NASDAQ: NGM) has reported results from the 24-week Phase 2b ALPINE 2/3 study evaluating aldafermin in non-alcoholic steatohepatitis (NASH) patients with stage 2 or 3 liver fibrosis (F2/F3).The study did not meet its primary endpoint evaluating a dose-response improvement in liver fibrosis by more than 1 stage with no worsening of NASH at week 24 (p=0.55).The study did achieve statistical significance versus placebo on specific secondary endpoints, including NASH resolution (at the 3 mg dose) and multiple non-invasive measures of NASH, including liver fat content (at the 1 mg and 3 mg doses).Given the failure to meet the primary endpoint, the company has decided not to pursue Phase 3 development of aldafermin in F2/F3 NASH; instead will focus on its ophthalmology and oncology portfolio.The overall safety profile of aldafermin was consistent with prior studies and similar to that of placebo.Patients treated with aldafermin at all three doses studied in the trial demonstrated a comparable frequency of adverse events versus placebo.Additionally, Merck & Co Inc (NYSE: MRK) continues the global Phase 2b development of MK-3655, an FGFR1c/KLB agonistic antibody for NASH treatment, which NGM discovered under its collaboration with Merck.NGM will host a conference call and webcast with a slide presentation at 8:30 a.m. ET today.Price Action: NGM shares are trading 45.4% lower $15.5 in the premarket session on the last check Monday.","news_type":1},"isVote":1,"tweetType":1,"viewCount":349,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"EN","currentLanguage":"EN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":16,"xxTargetLangEnum":"ORIG"},"commentList":[{"id":4434949,"commentId":"4434949","gmtCreate":1621877806204,"gmtModify":1680790713316,"authorId":3574428256060280,"author":{"id":3574428256060280,"idStr":"3574428256060280","authorId":3574428256060280,"name":"KinKin","avatar":"https://static.tigerbbs.com/b4f58c29c0c165071cb594bd19ce588a","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":131428145,"objectIdStr":"131428145","type":1,"supId":0,"supIdStr":"0","prevId":0,"prevIdStr":"0","content":"Pls reply","text":"Pls reply","html":"Pls reply","likeSize":0,"commentSize":2,"subComments":[{"id":4447175,"commentId":"4447175","gmtCreate":1621963315703,"gmtModify":1680790931427,"authorId":3574428256060280,"author":{"id":3574428256060280,"idStr":"3574428256060280","authorId":3574428256060280,"name":"KinKin","avatar":"https://static.tigerbbs.com/b4f58c29c0c165071cb594bd19ce588a","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":131428145,"objectIdStr":"131428145","type":1,"supId":4434949,"supIdStr":"4434949","prevId":0,"prevIdStr":"0","content":"Sure","text":"Sure","html":"Sure"},{"id":4435365,"commentId":"4435365","gmtCreate":1621893238921,"gmtModify":1680790714837,"authorId":3568230509761996,"author":{"id":3568230509761996,"idStr":"3568230509761996","authorId":3568230509761996,"name":"AndreR93","avatar":"https://static.tigerbbs.com/96d3de091542c3cf445343cfbe260aeb","vip":1,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":131428145,"objectIdStr":"131428145","type":1,"supId":4434949,"supIdStr":"4434949","prevId":0,"prevIdStr":"0","content":"Reply <u>pls</u>","text":"Reply <u>pls</u>","html":"Reply <u>pls</u>"}],"verified":10,"allocateAmount":0,"commentType":"invalid","coins":0,"score":0}],"hasMoreComment":true,"orderType":2}